Elsevier

Clinical Breast Cancer

Volume 8, Issue 5, October 2008, Pages 418-424
Clinical Breast Cancer

Original Contribution
Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible

https://doi.org/10.3816/CBC.2008.n.050Get rights and content

Abstract

Purpose

We conducted a pilot study of dose-dense epirubicin/cyclophosphamide (EC) × 6 → paclitaxel (P) × 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) × 6 with filgrastim → by weekly paclitaxel alternating with docetaxel × 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase). Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility.

Patients and Methods

Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal status. Treatment regimen consisted of every-2-week EC (100/600 mg/m2) × 6 → by 2-weekly P (175 mg/m2) × 6 with pegfilgrastim 6 mg on day 2.

Results

Between November 2004 and May 2005, 38 patients were enrolled. The median age was 47 years (range, 30-72 years); 33 of 38 (87%) were treated in the adjuvant setting and 27 of 33 (81%) had involved nodes (range, 1-46); 5 of 38 (13%) were treated pre-operatively; 33 of 38 (87%) completed all chemotherapy as planned; the remaining patients (13%) had treatment modifications for toxicity. Febrile neutropenia occurred in 6 of 38 patients (16 %) and only during EC. There were 12 hospitalizations in 9 of 38 patients (24%) enrolled.

Conclusion

Dose-dense every-2-week EC × 6 → P × 6 with pegfilgrastim is feasible based on our prospective definition.

References (44)

  • I Smith et al.

    2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial

    Lancet

    (2007)
  • JA Sparano et al.

    Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199

    Breast Cancer Res Treat

    (2005)
  • M Martin et al.

    Adjuvant docetaxel for node-positive breast cancer

    N Engl J Med

    (2005)
  • SE Jones et al.

    Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

    J Clin Oncol

    (2006)
  • The French Adjuvant Study Group

    Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial

    J Clin Oncol

    (2001)
  • H Joensuu et al.

    Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

    N Engl J Med

    (2006)
  • K Miller et al.

    Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

    N Engl J Med

    (2007)
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials

    Lancet

    (2005)
  • B Fisher et al.

    Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update

    Cancer

    (1983)
  • RA Saez et al.

    Prognostic factors in breast cancer

    Sem Surg Oncol

    (1989)
  • CT Dang et al.

    Cytokinetics

  • JM Nabholtz et al.

    Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial

    J Clin Oncol

    (2003)
  • J Jassem et al.

    Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial

    J Clin Oncol

    (2001)
  • IC Henderson et al.

    Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer

    J Clin Oncol

    (2003)
  • EP Mamounas et al.

    Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28

    J Clin Oncol

    (2005)
  • MN Levine et al.

    Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group MA.5

    J Clin Oncol

    (2005)
  • H Roche et al.

    Sequential adjuvant epirubicinbased and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial

    J Clin Oncol

    (2006)
  • M Martin et al.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    J Natl Cancer Inst

    (2008)
  • W Hryniuk et al.

    Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

    J Clin Oncol

    (1986)
  • DD Von Hoff et al.

    Use of in vitro dose-response effect to select antineoplastics for high-dose or regional administration regimens

    J Clin Oncol

    (1986)
  • B Fisher et al.

    Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

    J Clin Oncol

    (1997)
  • B Fisher et al.

    Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25

    J Clin Oncol

    (1999)
  • Cited by (0)

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text